Related Experiment Video
Updated: Aug 24, 2026

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
Cardiac remodeling in coronary artery disease
1Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. n.sharpe@auckland.ac.nz
Insights
Carvedilol prevents adverse cardiac remodeling in patients with coronary artery disease (CAD), improving long-term outcomes. This suggests targeting ventricular remodeling is key for CAD treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiac remodeling is a key driver of heart failure progression in coronary artery disease (CAD).
- Beta-blockers, specifically carvedilol, have demonstrated effects on cardiac remodeling.
Purpose of the Study:
- To evaluate the remodeling effects of carvedilol in patients with CAD.
- To determine if carvedilol's remodeling effects correlate with clinical outcomes.
Main Methods:
- Review of studies investigating carvedilol's impact on ventricular remodeling.
- Analysis of clinical outcomes in patients with left ventricular dysfunction post-myocardial infarction and chronic heart failure of ischemic etiology.
Main Results:
- Carvedilol was found to prevent progressive adverse ventricular remodeling in patients with CAD.
- This anti-remodeling effect is consistent with carvedilol's established benefits on long-term clinical outcomes.
Conclusions:
- Ventricular remodeling is a significant therapeutic target in CAD.
- Carvedilol likely mediates part of its clinical benefits by preventing adverse cardiac remodeling.
Abstract:
Cardiac remodeling is a central mechanism of heart failure progression in patients with coronary artery disease (CAD). The remodeling effect of beta-blockade with carvedilol has been studied in patients with left ventricular dysfunction after myocardial infarction and in patients with chronic heart failure of ischemic etiology. Carvedilol has been found to prevent progressive adverse ventricular remodeling in both conditions. This effect is concordant with the improvement in long-term clinical outcomes established for carvedilol in such patients. Thus, ventricular remodeling appears to be an important treatment target in patients with CAD and is likely to mediate at least part of the clinical improvement achieved with carvedilol.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease I: Introduction
Cardiomyopathy V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
